key: cord-0852406-hd2pz953 authors: Juul, S.; Nielsen, E. E.; Feinberg, J.; Siddiqui, F.; Joergensen, C. K.; Barot, E.; Holgersson, J.; Nielsen, N.; Bentzer, P.; Veroniki, A. A.; Thabane, L.; Bu, F.; Klingenberg, S.; Gluud, C.; Jakobsen, J. C. title: Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project) date: 2020-11-24 journal: nan DOI: 10.1101/2020.11.22.20236448 sha: ef5290e86dcc3b6aa27c48d4321a93414d9be17c doc_id: 852406 cord_uid: hd2pz953 Background COVID-19 is a rapidly spreading disease that has caused extensive burden to individuals, families, countries, and the world. Effective treatments of COVID-19 are urgently needed. This is the second edition of a living systematic review of randomized clinical trials assessing the effects of all treatment interventions for participants in all age groups with COVID-19. Methods and findings We planned to conduct aggregate data meta-analyses, trial sequential analyses, network meta-analysis, and individual patient data meta-analyses. Our systematic review was based on PRISMA and Cochrane guidelines, and our eight-step procedure for better validation of clinical significance of meta-analysis results. We performed both fixed-effect and random-effects meta-analyses. Primary outcomes were all-cause mortality and serious adverse events. Secondary outcomes were admission to intensive care, mechanical ventilation, renal replacement therapy, quality of life, and non-serious adverse events. According to the number of outcome comparisons, we adjusted our threshold for significance to p = 0.033. We used GRADE to assess the certainty of evidence. We searched relevant databases and websites for published and unpublished trials until November 2, 2020. Two reviewers independently extracted data and assessed trial methodology. We included 82 randomized clinical trials enrolling a total of 40,249 participants. 81 out of 82 trials were at overall high risk of bias. Meta-analyses showed no evidence of a difference between corticosteroids versus control on all-cause mortality (risk ratio [RR] 0.89; 95% confidence interval [CI] 0.79 to 1.00; p = 0.05; I2 = 23.1%; eight trials; very low certainty), on serious adverse events (RR 0.89; 95% CI 0.80 to 0.99; p = 0.04; I2 = 39.1%; eight trials; very low certainty), and on mechanical ventilation (RR 0.86; 95% CI 0.55 to 1.33; p = 0.49; I2 = 55.3%; two trials; very low certainty). The fixed-effect meta-analyses showed indications of beneficial effects. Trial sequential analyses showed that the required information size for all three analyses was not reached. Meta-analysis (RR 0.93; 95% CI 0.82 to 1.07; p = 0.31; I2 = 0%; four trials; moderate certainty) and trial sequential analysis (boundary for futility crossed) showed that we could reject that remdesivir versus control reduced the risk of death by 20%. Meta-analysis (RR 0.82; 95% CI 0.68 to 1.00; p = 0.05; I2 = 38.9%; four trials; very low certainty) and trial sequential analysis (required information size not reached) showed no evidence of difference between remdesivir versus control on serious adverse events. Fixed-effect meta-analysis showed indications of a beneficial effect of remdesivir on serious adverse events. Meta-analysis (RR 0.40; 95% CI 0.19 to 0.87; p = 0.02; I2 = 0%; two trials; very low certainty) showed evidence of a beneficial effect of intravenous immunoglobulin versus control on all-cause mortality, but trial sequential analysis (required information size not reached) showed that the result was severely underpowered to confirm or reject realistic intervention effects. Meta-analysis (RR 0.63; 95% CI 0.35 to 1.14; p = 0.12; I2 = 77.4%; five trials; very low certainty) and trial sequential analysis (required information size not reached) showed no evidence of a difference between tocilizumab versus control on serious adverse events. Fixed-effect meta-analysis showed indications of a beneficial effect of tocilizumab on serious adverse events. Meta-analysis (RR 0.70; 95% CI 0.51 to 0.96; p = 0.02; I2 = 0%; three trials; very low certainty) showed evidence of a beneficial effect of tocilizumab versus control on mechanical ventilation, but trial sequential analysis (required information size not reached) showed that the result was severely underpowered to confirm of reject realistic intervention effects. Meta-analysis (RR 0.32; 95% CI 0.15 to 0.69; p < 0.00; I2 = 0%; two trials; very low certainty) showed evidence of a beneficial effect of bromhexidine versus standard care on non-serious adverse events, but trial sequential analysis (required information size not reached) showed that the result was severely underpowered to confirm or reject realistic intervention effects. Meta-analyses and trial sequential analyses (boundary for futility crossed) showed that we could reject that hydroxychloroquine versus control reduced the risk of death and serious adverse events by 20%. Meta-analyses and trial sequential analyses (boundary for futility crossed) showed that we could reject that lopinavir-ritonavir versus control reduced the risk of death, serious adverse events, and mechanical ventilation by 20%. All remaining outcome comparisons showed that we did not have enough information to confirm or reject realistic intervention effects. Nine single trials showed statistically significant results on our outcomes, but were underpowered to confirm or reject realistic intervention effects. Due to lack of data, it was not relevant to perform network meta-analysis or possible to perform individual patient data meta-analyses. Conclusions No evidence-based treatment for COVID-19 currently exists. Very low certainty evidence indicates that corticosteroids might reduce the risk of death, serious adverse events, and mechanical ventilation; that remdesivir might reduce the risk of serious adverse events; that intraveneous immunoglobin might reduce the risk of death and serious adverse events; that tocilizumab might reduce the risk of serious adverse events and mechanical ventilation; and that bromhexidine might reduce the risk of non-serious adverse events. More trials with low risks of bias and random errors are urgently needed. This review will continuously inform best practice in treatment and clinical research of COVID-19. 0.05; I 2 = 38.9%; four trials; very low certainty) and trial sequential analysis (required information size not reached) showed no evidence of difference between remdesivir versus control on serious adverse events. Fixed-effect meta-analysis showed indications of a beneficial effect of remdesivir on serious adverse events. Meta-analysis (RR 0.40; 95% CI 0.19 to 0.87; p = 0.02; I 2 = 0%; two trials; very low certainty) showed evidence of a beneficial effect of intravenous immunoglobulin versus control on all-cause mortality, but trial sequential analysis (required information size not reached) showed that the result was severely underpowered to confirm or reject realistic intervention effects. Meta-analysis (RR 0.63; 95% CI 0.35 to 1.14; p = 0.12; I 2 = 77.4%; five trials; very low certainty) and trial sequential analysis (required information size not reached) showed no evidence of a difference between tocilizumab versus control on serious adverse events. Fixed-effect meta-analysis showed indications of a beneficial effect of tocilizumab on serious adverse events. Meta-analysis (RR 0.70; 95% CI 0.51 to 0.96; p = 0.02; I 2 = 0%; three trials; very low certainty) showed evidence of a beneficial effect of tocilizumab versus control on mechanical ventilation, but trial sequential analysis (required information size not reached) showed that the result was severely underpowered to confirm of reject realistic intervention effects. Meta-analysis (RR 0.32; 95% CI 0.15 to 0.69; p < 0.00; I 2 = 0%; two trials; very low certainty) showed evidence of a beneficial effect of bromhexidine versus standard care on non-serious adverse events, but trial sequential analysis (required information size not reached) showed that the result was severely underpowered to confirm or reject realistic intervention effects. Meta-analyses and trial sequential analyses (boundary for futility crossed) showed that we could reject that hydroxychloroquine versus control reduced the risk of death and serious adverse events by 20%. Meta-analyses and trial sequential analyses (boundary for futility crossed) showed that we could reject that lopinavir-ritonavir versus control reduced the risk of death, serious adverse events, and mechanical ventilation by 20%. All remaining outcome comparisons showed that we did not have enough information to confirm or reject realistic intervention effects. Nine single trials showed statistically significant results on our outcomes, but were underpowered to confirm or reject realistic intervention effects. Due to lack of data, it was not relevant to perform network meta-analysis or possible to perform individual patient data meta-analyses. No evidence-based treatment for COVID-19 currently exists. Very low certainty evidence indicates that corticosteroids might reduce the risk of death, serious adverse events, and mechanical ventilation; that remdesivir might reduce the risk of serious adverse events; that intraveneous immunoglobin might reduce the risk of death and serious adverse events; that tocilizumab might reduce the risk of serious adverse events and mechanical ventilation; and that bromhexidine might reduce the risk of non-serious adverse events. More trials with low risks of bias and random errors are urgently needed. This review will continuously inform best practice in treatment and clinical research of COVID-19. Author summary Why was this study done? • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has spread rapidly worldwide, causing an international outbreak of the corona virus disease 2019 . • There is a need for a living systematic review evaluating the beneficial and harmful effects of all possible interventions for treatment of COVID-19. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020. 11.22.20236448 doi: medRxiv preprint What did the researchers do and find? • We conducted the second edition of our living systematic review with meta-analyses and Trial sequential analyses to compare the effects of all treatment interventions for COVID-19. • Very low certainty evidence indicated that corticosteroids might reduce the risk of death, serious adverse events, and mechanical ventilation; that remdesivir might reduce the risk of serious adverse events; that intraveneous immunoglobin might reduce the risk of death and serious adverse events; that tocilizumab might reduce the risk of serious adverse events and mechanical ventilation; and that bromhexidine might reduce the risk of non-serious adverse events. • Nine single trials showed statistically significant results on our predefined outcomes but were underpowered to confirm or reject realistic intervention effects. • None of the remaining trials showed evidence of a difference of the experimental interventions on our predefined outcomes. What do these findings mean? • No evidence-based treatment for COVID-19 currently exists • More high quality, low risk of bias randomized clinical trials are urgently needed. In 2019, a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused an international outbreak of the respiratory illness COVID-19 [1] . Since the initial outbreak in China, SARS-CoV-2 has spread globally and COVID-19 is labeled a public health emergency of global concern by the World Health Organization [2] . The full spectrum of COVID-19 ranges from subclinical infection over mild, self-limiting respiratory tract illness to severe progressive pneumonia, multiorgan failure, and death [3] . Severe disease onset might result in death due to massive alveolar damage and progressive respiratory failure [4] [5] [6] . Many randomized clinical trials assessing the effects of different potential treatments for COVID-19 are currently underway. However, a single trial can rarely validly assess the effects of any intervention and there is an urgent need to continuously surveil and update the aggregated evidence base so that effective interventions, if such exist, are implemented in clinical practice [7] . The present living systematic review with aggregate meta-analyses and trial sequential analyses aims to continuously inform evidence-based guideline recommendations for the treatment of COVID-19, taking risks of systematic errors ('bias'), risks of random errors ('play of chance'), and certainty of the findings into consideration [8] . We report this systematic review based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines (S1 Text) [9, 10] . The updated methodology used in this . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236448 doi: medRxiv preprint living systematic review is according to the Cochrane Handbook of Systematic Reviews of Interventions [11] and described in our protocol [8] , which was registered in the PROSPERO database (ID: CRD42020178787) prior to the systematic literature search. The reference lists of relevant trial publications were checked for any unidentified randomized clinical trials. To identify unpublished trials, we searched clinical trial registries (e.g. clinicaltrials.gov, clinicaltrialregister.eu, who.int/ictrp, chictr.org.cn) of Europe, USA, and China, and websites of pharmaceutical companies and of U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA). We also searched the COVID-19 Study Registry [12] and the real-time dashboard of randomized trials [13] . . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020. 11.22.20236448 doi: medRxiv preprint We included unpublished and grey literature trials and assessed relevant retraction statements and errata for included trials. We also searched preprint servers (bioRxiv, medRxiv) for unpublished trials. We contacted all corresponding authors to obtain individual patient data. In this living systematic review, two independent investigators receive a weekly updated literature search file, and continuously include relevant newly published or unpublished trials. The relevant meta-analyses, trial sequential analyses, and network meta-analysis will be continuously updated, and if new evidence is available (judged by the author group), the results will be submitted for publication. Every month, the author group will discuss whether searching once a week is necessary. For a detailed overview of the living systematic review work flow, see our protocol [8] . As this is a living systematic review analyzing results of randomized clinical trials, no ethical approval is required. Two authors (EEN and JF) independently screened relevant trials. Seven authors in pairs (SJ, EEN, JF, FS, CKJ, EB, JH) independently extracted data using a standardized data extraction sheet. Any discrepancies were resolved through discussion, or if required, through discussion with a third author (JCJ). We contacted corresponding authors if relevant data were unclear or missing. Risk of bias was assessed with the Cochrane Risk of Bias tool -version 2 (RoB 2) [11, 14] . Seven authors in pairs (SJ, EEN, JF, FS, CKJ, EB, JH) independently assessed risk of bias. Any therefore adjusted our thresholds for significance [17] and considered a p-value of 0.033 or less as the threshold for statistical significance [8, 17] . Because we primarily considered results of secondary outcomes as hypothesis generating, we did not adjust the p-value for secondary outcomes. We conducted both random-effects (DerSimonian-Laird) and fixed-effect (Mantel-Haenszel) meta-analyses for all analyses and chose the most conservative result as our primary result [11, 17, 20, 21] . We used trial sequential analysis to control for random errors [22] [23] [24] [25] [26] [27] [28] [29] [30] . Trial sequential analysis estimates the diversity-adjusted required information size (DARIS), which is the number of participants needed in a meta-analysis to detect or reject a certain intervention effect. Statistical heterogeneity was quantified by calculating heterogeneity (I 2 ) for traditional metaanalyses and diversity (D 2 ) for trial sequential analysis. We used Grading Recommendations Assessment Development Evaluation (GRADE) to assess the certainty of evidence. We downgraded imprecision in GRADE by two levels if the accrued number of participants were below 50% of the DARIS, and one level if between 50% and 100% of DARIS [17] . We did not downgrade if benefit, harm, futility or DARIS were reached. We used Fisher's exact test to calculate p-values for all single trial results. On November 2, 2020 our literature searches identified 15,359 records after duplicates were removed. We included a total of 82 clinical trials randomizing 40,249 participants (Fig 1) [31 -114] . We identified several trials including participants suspected of COVID-19 [115, 116] . None of the trials reported separate data on COVID-19 positive participants compared to the remaining participants. We included trials if approximately 50% or more participants had a confirmed . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236448 doi: medRxiv preprint COVID-19 diagnosis. We wrote to all authors requesting separate data on COVID-19 confirmed participants, but we have received no responses yet. For at detailed overview of excluded trials, see S1 Table. Most trials were at high risk of bias (S3 Table) . [41, 67] or a co-intervention alone [114] . . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2020. [75] ; vitamin C versus placebo [76] ; sofosbuvir plus . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2020. We identified 10 trials (11 comparisons) . We contacted the trial authors and asked for separate data for all randomized participants, but did not receive any response. Another trial assessing the effects of methylprednisolone was not eligible for . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236448 doi: medRxiv preprint meta-analysis, as the trial did not report on any of our review outcomes [96] . We requested data for our review outcomes from the trial authors but did not receive a response. Random-effects meta-analysis showed no evidence of a difference between corticosteroids and control on all-cause mortality (RR 0.89; 95% CI 0.79 to 1.00; p = 0.05; I 2 = 23.1%; eight trials; very low certainty) (Fig 2, S4 Table) . Fixed-effect meta-analysis showed evidence of a beneficial effect of corticosteroids versus control on all-cause mortality (RR 0.88; 95% CI 0.82 to 0.95; p = 0.00; I 2 = 23.6%, eight trials) (S1 Fig). Visual inspection of the forest plot and measures to quantify heterogeneity (I 2 = 23.1%) indicated no substantial heterogeneity. The time-points of assessment varied from 21 [88] to 30 days after randomization [97, 118] . The trial sequential analysis showed that we did not have enough information to confirm or reject that corticosteroids versus control reduce the risk of all-cause mortality with a relative risk reduction of 20% (Fig 3) . The subgroup analysis assessing the effects of the different corticosteroids versus control showed no significant subgroup differences (p = 0.57) (Fig 2) . The subgroup analysis assessing the effects of disease severity as defined by trialists (mild, moderate, severe, or a combination) showed no significant Random-effects meta-analysis showed no evidence of a difference between corticosteroids and control on serious adverse events (RR 0.89; 95% CI 0.80 to 0.99; p = 0.04; I 2 = 39.1%; eight trials; very low certainty) (S3 Fig, S4 Table) . Random-effects meta-analysis showed no evidence of a difference between corticosteroids versus control on mechanical ventilation (RR 0.86; 95% CI 0.55 to 1.33; p = 0.49; I 2 = 55.3%; two trials; very low certainty) (S6 Fig, S4 Table) . is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236448 doi: medRxiv preprint assessment varied from 7 days [68] to 28 days after randomization [47] . The trial sequential analysis showed that we did not have enough information to confirm or reject that corticosteroids versus control reduce the risk of receiving mechanical ventilation with a relative risk reduction of 20% (S8 Fig). The subgroup analysis assessing the effects of the different corticosteroids versus control showed no significant subgroup differences (p = 0.13) (S6 Fig). One of the two trials [68] had substantial missing data for this outcome, but it was a small trial that did not contribute with much data compared to the second trial. We identified four trials randomizing 7,370 participants to remdesivir versus standard care [86, 110] or placebo [43, 65] . All trials were assessed at high risk of bias (S3 Table) . One trial assessed two different dosages of remdesivir versus standard care [86] , and the two comparisons were both included in the meta-analysis. We halved the control group to avoid double counting [11] . Random-effects meta-analysis showed no evidence of a difference between remdesivir versus control on all-cause mortality (RR 0.93; 95% CI 0.82 to 1.07; p = 0.31; I 2 = 0%; four trials; moderate certainty) (Fig 4, S5 Table) . Visual inspection of the forest plot and measures to quantify heterogeneity (I 2 = 0%) indicated no heterogeneity. The assessment time points were 28 [43, 86, 110] and 29 days after randomization [65] . The trial sequential analysis showed that we had enough information to reject that remdesivir versus control reduces the risk of all-cause mortality with a relative risk reduction of 20% (Fig 5) . The subgroup analysis assessing the effects of the different control interventions showed no significant subgroup differences (p = 0.21) (Fig 4) . The subgroup . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Random-effects meta-analysis showed no evidence of difference between remdesivir versus control on serious adverse events (RR 0.82; 95% CI 0.68 to 1.00; p = 0.05; I 2 = 38.9%; four trials; very low certainty) (S10 Fig, S5 Table) . . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236448 doi: medRxiv preprint Random-effects meta-analysis showed no evidence of a difference between remdesivir versus control on mechanical ventilation (RR 0.73; 95% CI 0.42 to 1.27; p = 0.27; I 2 = 83.1%; three trials; very low certainty) (S13 Fig, S5 Table) . Visual inspection of the forest plot and measures to quantify heterogeneity (I 2 = 83.1%) indicated substantial heterogeneity. The assessment time points were 28 [43,110] and 29 days after randomization [65]. The trial sequential analysis showed that we did not have enough information to confirm or reject that remdesivir versus control reduces the risk of receiving mechanical ventilation with a relative risk reduction of 20% (S14 Fixed-effect meta-analysis showed no evidence of a difference between remdesivir versus control on non-serious adverse events (RR 0.99; 95% CI 0.91 to 1.08; p = 0.86; I 2 = 56.4%; three trials; very low certainty) (S15 Fig, S5 Table) . Visual inspection of the forest plot and measures to quantify heterogeneity (I 2 = 56.4%) indicated moderate heterogeneity. The assessment time point was 28 days after randomization [43,65,86]. The Trial Sequential Analysis showed that we had enough information to reject that remdesivir versus control reduces the risk of non-serious adverse events with a relative risk reduction of 20% (S16 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236448 doi: medRxiv preprint We identified 13 trials randomizing 10,276 participants to hydroxychloroquine versus standard care [34, 35, 42, 48, 54, 55, 58, 59, 105, 110] , or placebo [53,108]. All trials were assessed at high risk of bias (S3 Table) . One trial was not eligible for meta-analysis, as the results were not reported in a usable way; i.e., the results were reported as per-protocol and several participants crossed over [42] . Fixed-effect meta-analysis showed no evidence of a difference between hydroxychloroquine versus control on all-cause mortality (RR 1.09; 95% CI 0.99 to 1.20; p = 0.08; I 2 = 0%; 10 trials; moderate certainty) (S17 Fig, S6 Table) . Visual inspection of the forest plot and measures to quantify heterogeneity (I 2 = 0%) indicated no heterogeneity. The assessment time points varied from five days after randomization [34, 35] to 30 days after randomization [108]. The trial sequential analysis showed that we had enough information to reject that hydroxychloroquine versus control reduces the risk of all-cause mortality with a relative risk reduction of 20% (S18 Fixed-effect meta-analysis showed no evidence of a difference between hydroxychloroquine versus control on serious adverse events (RR 1.08; 95% CI 0.98 to 1.19; p = 0.11; I 2 = 0%; 11 trials; moderate certainty) (S19 Fig, S6 Table) . Visual inspection of the forest plot and measures to quantify heterogeneity (I 2 = 0%) indicated no heterogeneity. The assessment time points varied from five days after randomization [34, 35] to 30 days after randomization [108]. The trial sequential analysis showed that we had enough information to reject that hydroxychloroquine . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236448 doi: medRxiv preprint versus control reduces the risk of serious adverse events with a relative risk reduction of 20% (S20 Fixed-effect meta-analysis showed no evidence of a difference between hydroxychloroquine versus control on admission to intensive care (RR 0.74; 95% CI 0.44 to 1.25; p = 0.26; I 2 = 0%; two trials; very low certainty) (S21 Fig, S6 Table) . Visual inspection of the forest plot and measures to quantify heterogeneity (I 2 = 0%) indicated no substantial heterogeneity. The assessment time points were 28 days after randomization [77] and 30 days after randomization [108]. The trial sequential analysis showed that we did not have enough information to confirm or reject that hydroxychloroquine versus control reduces the risk of admission to intensive care with a relative risk reduction of 20% (S22 Fig) . The subgroup analysis assessing the effects of hydroxychloroquine versus different control interventions showed no significant subgroup differences (p = 0.61) (S21 Fixed-effect meta-analysis showed no evidence of a difference between hydroxychloroquine versus control on mechanical ventilation (RR 1.10; 95% CI 0.84 to 1.45; p = 0.48; I 2 = 0.00%; four trials; very low certainty) (S23 Fig, S6 Table) . Visual inspection of the forest plot and measures to quantify heterogeneity (I 2 = 0%) indicated no heterogeneity. The assessment time points were 15 days after randomization [54] and 30 days after randomization [108]. The trial sequential analysis showed that we did not have enough information to confirm or reject that hydroxychloroquine versus control reduces the risk of receiving mechanical ventilation with a relative risk reduction of . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Random-effects meta-analysis showed evidence of a harmful effect of hydroxychloroquine versus control on non-serious adverse events (RR 2.09; 95% CI 1.14 to 3.80; p = 0.02; I 2 = 92.1%; six trials; very low certainty) (S25 Fig, S6 Table) We identified four trials randomizing 8,081 participants to lopinavir-ritonavir versus standard care [32, 40, 106, 110] . We also identified one trial randomising 60 participants to lopinavir-ritonavir and novaferon versus novaferon alone [45] . All trials were assessed at high risk of bias (S3 Table) . Fixed-effect meta-analysis showed no evidence of a difference between lopinavir-ritonavir versus control on all-cause mortality (RR 1.01; 95% CI 0.92 to 1.12; p = 0.77; I 2 = 0.0%; five trials; moderate certainty) (S26 Fig, S7 Table) . Visual inspection of the forest plot and measures to . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236448 doi: medRxiv preprint quantify heterogeneity (I 2 = 0.0%) indicated no heterogeneity. The time-points of assessment were nine days after randomization in one trial [45] , 21 days after randomization in one trial [40] , 28 days after randomization in two trials [32,110], and 28 days or until discharge or death in one trial [106] . The trial sequential analysis showed that we had enough information to reject that lopinavirritonavir versus control reduces the risk of all-cause mortality with a relative risk reduction of 20% Random-effects meta-analysis showed no evidence of a difference between lopinavir-ritonavir versus control on serious adverse events (RR 1.00; 95% CI 0.91 to 1.11; p = 0.93; I 2 = 1.2%; five trials; moderate certainty) (S28 Fig, S7 Table) . Visual inspection of the forest plot and measures to quantify heterogeneity (I 2 = 1.2%) indicated no substantial heterogeneity. The time-points of assessment were nine days after randomization in one trial [45] , 21 days after randomization in one trial [40] , 28 days after randomization in two trials [32,110], and 28 days or until discharge or death in one trial [106] . The trial sequential analysis showed that we had enough information to reject that lopinavir-ritonavir versus control reduces the risk of serious adverse events with a relative risk . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236448 doi: medRxiv preprint Random-effects meta-analysis showed no evidence of a difference between lopinavir-ritonavir versus control on mechanical ventilation (RR 1.08; 95% CI 0.94 to 1.25; p = 0.29; I 2 = 0.0%; three trials; moderate certainty) (S30 Fig 2, S7 Table) . Visual inspection of the forest plot and measures to quantify heterogeneity (I 2 = 0.0%) indicated no heterogeneity. The time-points of assessment were 28 days after randomization in two trials [32,79] and 28 days or until discharge or death for one trial [106] . The trial sequential analysis showed that we had enough information to reject that lopinavir-ritonavir versus control reduces the risk of receiving mechanical ventilation with a relative risk reduction of 20% (S31 Fig) . Random-effects meta-analysis showed no evidence of a difference between lopinavir-ritonavir versus control on renal replacement therapy (RR 0.97; 95% CI 0.73 to 1.28; p = 0.81; I 2 = 0.0%; two trials; very low certainty) (S32 Fig, S7 Table) . Visual inspection of the forest plot and measures to quantify heterogeneity (I 2 = 0.0%) indicated no heterogeneity. The time-points of assessment was 28 days for the first trial [32] and 28 days or until discharge or death for the second trial [106] . The trial sequential analysis showed that we did not have enough information to confirm or reject that lopinavir-ritonavir versus control reduces the risk of renal replacement therapy with a relative risk reduction of 20% (S33 Fig) . Random-effects meta-analysis showed no evidence of a difference between lopinavir-ritonavir versus standard care on non-serious adverse events (RR 1.14; 95% CI 0.85-1.53; p = 0.38, I 2 = 75%; two trials; very low certainty) (S34 Fig; S7 Table) . Visual inspection of the forest plot and . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236448 doi: medRxiv preprint measures to quantify heterogeneity (I 2 = 75%) indicated substantial heterogeneity. The assessment time point was 21 days after randomization in the first trial [40] and 28 days after randomization in the second trial [3] . The trial sequential analysis showed that we did not have enough information to confirm or reject that lopinavir-ritonavir compared with standard care reduces nonserious adverse events with a relative risk reduction of 20%. We identified two trials randomizing 4,219 participants to interferon β -1a versus standard care [36, 110] . In one of the trials, the first 1,200 participants received interferon β -1a and lopinavirritonavir or lopinavir-ritonavir alone, while the remaining 2,927 participants received interferon β -1a or standard care [110] . All trials were assessed at high risk of bias (S3 Table) . Random-effects meta-analysis showed no evidence of a difference between interferon β -1a versus standard care on all-cause mortality (RR 0.75; 95% CI 0.30 to 1.88; p = 0.54; I 2 = 84.1%; two trials; very low certainty) (S35 Fig, S8 Table) . Visual inspection of the forest plot and measures to quantify heterogeneity (I 2 = 84.1%) indicated substantial heterogeneity. The time-point of assessment was 28 days after randomization in both trials [36, 110] . The trial sequential analysis showed that we did not have enough information to confirm or reject that interferon β -1a versus standard care reduces the risk of all-cause mortality with a relative risk reduction of 20%. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236448 doi: medRxiv preprint Random-effects meta-analysis showed no evidence of a difference between interferon β -1a versus standard care on serious adverse events (RR 0.75; 95% CI 0.30 to 1.88; p = 0.54; I 2 = 84.1%; two trials; very low certainty) (S36 Fig, S8 Table) . However, the data was solely based on all-cause mortality data, since no other serious adverse events were reported [15] . Visual inspection of the forest plot and measures to quantify heterogeneity (I 2 = 84.1%) indicated substantial heterogeneity. The time-point of assessment was 28 days after randomization in both trials [36, 110] . The trial sequential analysis showed that we did not have enough information to confirm or reject that interferon β -1a versus standard care reduces the risk of serious adverse events with a relative risk reduction of 20%. We identified four trials randomizing 734 participants to convalescent plasma versus standard care [39, 51, 78, 91] . All trials were assessed as at high risk of bias (S3 Table) . Random-effects meta-analysis showed no evidence of difference between convalescent plasma versus standard care on all-cause mortality (RR 0.77; 95% CI 0.47 to 1.24; p = 0.28; I 2 = 27.5%; four trials; very low certainty) (S37 Fig, S9 Table) . Visual inspection of the forest plot and measures to quantify heterogeneity (I 2 = 27.5%) indicated some heterogeneity. The outcome was assessed 28 days after randomization in two trials [39, 91] , at 29 days after randomization in one trial [78] and up to hospital discharge or 60 days in one trial [51] . The trial sequential analysis showed that we did not have enough information to confirm or reject that convalescent plasma . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236448 doi: medRxiv preprint versus standard care reduces the risk of all-cause mortality with a relative risk reduction of 20% Fixed-effect meta-analysis showed no evidence of a difference between convalescent plasma versus standard care on serious adverse events (RR 0.93; 95% CI 0.64 to 1.35; p = 0.70; I 2 = 0.0%; three trials; very low certainty) (S39 Fig, S9 Table) . Visual inspection of the forest plot and measures to quantify heterogeneity (I 2 = 0.0%) indicated no substantial heterogeneity. The time-point of assessment was 28 days after randomization in two trials [39, 91] . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236448 doi: medRxiv preprint Fixed-effect meta-analysis showed no evidence of a difference between azithromycin versus control on all-cause mortality (RR 0.99; 95% CI 0.79 to 1.25; p = 0.95; I 2 = 7.4%; three trials; very low certainty) (S41 Fig, S10 Table) . Random-effects meta-analysis showed no evidence of a difference between azithromycin versus control on serious adverse events (RR 0.95; 95% CI 0.55 to 1.63; p = 0.84; I 2 = 16%; three trials; very low certainty) (S43 Fig, S10 Table) . Visual inspection of the forest plot and measures to quantify heterogeneity (I 2 = 16%) indicated no substantial heterogeneity. The time-point of assessment was 15 days after randomization in the first trial [54], and 29 days after randomization in the second trial [83] , and unclear in the third trial [82] . We have contacted the trial authors and requested information on the assessment time-point, but we have not received a response yet. The trial sequential analysis showed that we did not have enough information to confirm or reject that azithromycin versus control reduces the risk of serious adverse events with a relative risk reduction . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236448 doi: medRxiv preprint of 20%. The subgroup analysis assessing the effects of azithromycin versus different control interventions showed no significant subgroup differences (p = 0.30) (S43 Fig) . Fixed-effect meta-analysis showed no evidence of a difference between azithromycin versus control on mechanical ventilation (RR 1.07; 95% CI 0.59 to 1.94; p = 0.83; I 2 = 53%; two trials; very low certainty) (S44 Fig, S10 Table) . Fixed-effect meta-analysis showed no evidence of a difference between azithromycin versus control on non-serious adverse events (RR 1.09; 95% CI 0.89 to 1.34; p = 0.38; I 2 = 0%; two trials; very low certainty) (S45 Fig, S10 Table) . Visual inspection of the forest plot and measures to quantify heterogeneity (I 2 = 0%) indicated no heterogeneity. The time-point of assessment was 15 days after randomization in the first trial [54], and 29 days after randomization in the second trial [83] . The trial sequential analysis showed that we did not have enough information to confirm or reject that azithromycin versus control reduces the risk of non-serious adverse events with a relative risk . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table) . Fixed-effect meta-analysis showed no evidence of a difference between colchicine versus control on all-cause mortality (RR 1.03; 95% CI 0.07 to 16.01; p = 0.98; I 2 = 0%; two trials; very low certainty) (S47 Fig, S11 Table) . Visual inspection of the forest plot and measures to quantify heterogeneity (I 2 = 0%) indicated no heterogeneity. The time-point of assessment was unclear in both trials [92, 107] . We have contacted the trial authors and requested information on the assessment time-points, but we have not received a response yet. The trial sequential analysis showed that we did not have enough information to confirm or reject that colchicine versus control reduces the risk of all-cause mortality with a relative risk reduction of 20%. The subgroup analysis assessing the effects of colchicine versus different control interventions showed no evidence of a significant subgroup difference (p = 0.98) (S47 Fig) . Random-effects meta-analysis showed no evidence of a difference between colchicine versus control on non-serious adverse events (RR 0.88; 95% CI 0.18 to 4.39; p = 0.87; I 2 = 79.1%; three . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236448 doi: medRxiv preprint trials; very low certainty) (S48 Fig, S11 Table) . Visual inspection of the forest plot and measures to quantify heterogeneity (I 2 = 79.1%) indicated substantial heterogeneity. The time-point of assessment was 21 days after randomization in one trial [49] , but unclear in the other two trials [92, 107] . We have contacted the trial authors and requested information on the assessment timepoints, but we have not received a response yet. The trial sequential analysis showed that we did not have enough information to confirm or reject that colchicine versus control reduces the risk of nonserious adverse events with a relative risk reduction of 20%. The subgroup analysis assessing the effects of colchicine versus different control interventions showed evidence of significant subgroup We identified two trials randomizing 93 participants to intravenous immunoglobulin versus standard care [57] or placebo [95] . Both trials included immunoglobulin from healthy donors [57, 95] . Both trials were assessed at high risk of bias (S3 Table) . Fixed-effect meta-analysis showed evidence of a beneficial effect of intravenous immunoglobulin versus control on all-cause mortality (RR 0.40; 95% CI 0.19 to 0.87; p = 0.02; I 2 = 0%; two trials; very low certainty) (S49 Fig, S12 Table) . Visual inspection of the forest plot and measures to quantify heterogeneity (I 2 = 0%) indicated no heterogeneity. The outcome was assessed only in hospital in the first trial [95] and up to 30 days in the second trial [57] . The trial sequential analysis showed that we did not have enough information to confirm or reject that intravenous immunoglobulin versus control reduces the risk of all-cause mortality with a relative risk reduction of 20% (S50 Fig). The subgroup analysis assessing the effects of different control interventions . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236448 doi: medRxiv preprint showed no evidence of a significant subgroup difference between placebo and standard care (p = 0.89) (S49 Fig) Fixed-effect meta-analysis showed evidence of a beneficial effect of intravenous immunoglobulin versus control on serious adverse events (RR 0.40; 95% CI 0.19 to 0.87; p = 0.02; I 2 = 0%; two trials; very low certainty) (S51 Fig, S12 Table) . This data is solely based on all-cause mortality We identified six trials randomizing 1038 patients to tocilizumab versus standard care [93, [111] [112] [113] , placebo with standard care [90] or favipiravir alone as co-intervention [114] . All trials were assessed as at high risk of bias (S3 Table) . Random-effects meta-analysis showed no evidence of a difference between tocilizumab and control interventions on all-cause mortality (RR 1.03; 95% CI 0.72 to 1.46; p = 0.89; I 2 = 0.0%; four . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236448 doi: medRxiv preprint trials; very low certainty) (S53 Fig, S13 Table) . Visual inspection of the forest plot and measures to quantify heterogeneity (I 2 = 0.0%) indicated no heterogeneity. The time-points of assessment were 28 days [90, 111, 113] and 30 days [112] after randomization. The trial sequential analysis showed that we did not have enough information to confirm or reject that tocilizumab versus control reduces the risk of all-cause mortality with a relative risk reduction of 20% (S54 Fig). The subgroup analysis assessing the effects of different control interventions showed no significant subgroup differences (p = 0.87) (S53 Fig) Random-effects meta-analysis showed no evidence of a difference between tocilizumab and control interventions on serious adverse events (RR 0.63; 95% CI 0.35 to 1.14; p = 0.12; I 2 = 77.4%; five trials; very low certainty) (S55 Fig, S13 Table) . [111, 113] , or 30 days [112] after randomization. The trial sequential analysis showed that we did not have enough information to confirm or reject that tocilizumab versus control reduces the risk of serious adverse events with a relative risk reduction of 20%. The subgroup analysis assessing the effects of different control interventions showed no significant subgroup differences (p = 0.13) (S55 Fig) . Random-effects meta-analysis showed no evidence of a difference between tocilizumab and control interventions on admission to intensive care (RR 0.71; 95% CI 0.37 to 1.38; p = 0.32; I 2 = 36%; two . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236448 doi: medRxiv preprint trials; very low certainty) (S57 Fig, S13 Table) . Visual inspection of the forest plot and measures to quantify heterogeneity (I 2 = 36%) indicated no substantial heterogeneity. The time-point of assessment was either unclear [90] or 30 days [112] after randomization. The trial sequential analysis showed that we did not have enough information to confirm or reject that tocilizumab versus control reduces the risk of admission to intensive care with a relative risk reduction of 20%. The subgroup analysis assessing the effects of control interventions showed no significant subgroup differences (p = 0.21) (S57 Fig) . Random-effects meta-analysis showed evidence of a beneficial effect of tocilizumab versus control on mechanical ventilation (RR 0.70; 95% CI 0.51 to 0.96; p = 0.02; I 2 = 0%; three trials; very low certainty) (S58 Fig, S13 Table) . Visual inspection of the forest plot and measures to quantify heterogeneity (I 2 = 0%) indicated no heterogeneity. The time-point of assessment was either unclear [90] or 28 days [111, 113] after randomization. The trial sequential analysis showed that we did not have enough information to confirm or reject that tocilizumab reduce the risk of mechanical ventilation with a relative risk reduction of 20% (S59 Fig). The subgroup analysis assessing the effects of control interventions showed no significant subgroup differences (p = 0.34) (S58 Fig) . Fixed-effect meta-analysis showed no evidence of a difference between tocilizumab versus control on non-serious adverse events (RR 1.03; 95% CI 0.92 to 1.14; p = 0.63; I 2 = 57.9%; five trials; very low certainty) (S60 Fig, S13 Table) . Visual inspection of the forest plot and measures to quantify heterogeneity (I 2 = 57.9%) indicated moderate heterogeneity. The time-point of assessment was either unclear [90,93,114], 28 days [111] , or 30 days [112] after randomization. The trial sequential . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236448 doi: medRxiv preprint analysis showed that we did not have enough information to confirm or reject that tocilizumab versus control reduces the risk of non-serious adverse events with a relative risk reduction of 20%. The subgroup analysis assessing the effects of different control interventions showed no significant subgroup differences (p = 0.27) (S60 Fig). We identified two trials randomizing 96 participants to bromhexidine versus standard care [94, 104] . Both trials were assessed at high risk of bias (S3 Table) . Random-effects meta-analysis showed no evidence of a difference between bromhexidine versus standard care on all-cause mortality (RR 0.17; 95% CI 0.02 to 1.70; p = 0.13; I 2 = 0%; two trials; very low certainty certainty) (S61 Fig, S14 Table) . Visual inspection of the forest plot and measures to quantify heterogeneity (I 2 = 0%) indicated no heterogeneity. The time-point of assessment was 28 days for the first trial [104] and unclear for the second trial [94]. The trial sequential analysis showed that we did not have enough information to confirm or reject that bromhexidine versus standard care reduces the risk of all-cause mortality with a relative risk reduction of 20%. Random-effects meta-analysis showed evidence of a beneficial effect of bromhexidine versus standard care on non-serious adverse events (RR 0.32; 95% CI 0.15 to 0.69; p < 0.00; I 2 = 0%; two trials; very low certainty) (S62 Fig, S14 Table) . Visual inspection of the forest plot and measures to quantify heterogeneity (I 2 = 0%) indicated no heterogeneity. The time-point of assessment was 28 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236448 doi: medRxiv preprint days for the first trial [104] and unclear for the second trial [94] . The trial sequential analysis showed that we did not have enough information to confirm or reject that bromhexidine versus standard care reduces the risk of non-serious adverse events with a relative risk reduction of 20%. Because of lack of relevant data, it was not possible to conduct other meta-analyses, individual patient data meta-analyses, or network meta-analysis. Nine single trials showed statistically significant results but were all underpowered to confirm or reject realistic intervention effects. One trial randomizing 402 participants compared five versus ten days of remdesivir and showed evidence of a beneficial effect of five days of remdesivir on serious adverse events (p = 0.003 (Fisher's exact test)) [37] . One trial randomizing 92 participants compared the immunomodulator interferon β -1a added to standard care versus standard care alone and showed evidence of a beneficial effect of interferon β -1a on all-cause mortality (p = 0.029) [36] . This trial also showed evidence of a harmful effect of interferon β -1a on non-serious adverse events (p = 0.006) [36] . One None of the remaining single trial results showed evidence of a difference on our predefined review outcomes. Two trials did not report the results in a usable way; one trial reported results of the experimental group with a proportion of participants being non-randomized [56] , and the second trial reported the results as per-protocol, and there was participant crossover [42] . Seven trials did not report on our review outcomes [44, 62, 63, 67, 71, 96, 101] . We have contacted all corresponding authors, but we have not been able to obtain outcomes for our analyses from the trialists yet. Most trials were assessed at high risk of bias (S3 Table) . Characteristics of the trials and their results on the review outcomes can be found in S2 Table. Certainty of the evidence was assessed as 'low' or 'very low' for all outcomes (S15-S66 Table) . . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236448 doi: medRxiv preprint On November 2, 2020, a search on the Cochrane COVID-19 Study Register revealed 2527 registered randomized clinical trials [13] . From these, 106 different interventions for treatment of COVID-19 patients were identified [13] . The ten most investigated experimental interventions were hydroxychloroquine (162 trials), convalescent plasma (55 trials), azithromycin (52 trials), lopinavir and ritonavir (40 trials), tocilizumab (33 trials), chloroquine (30 trials), favipiravir (24 trials), remdesivir (15 trials), sarilumab (15 trials), and dexamethasone (13 trials). Eligible trials will continuously be included in the present living systematic review once results become available. We conducted the second edition of our living systematic review assessing the beneficial and harmful effects of any intervention for COVID-19. We searched relevant databases and websites for published and unpublished trials until November 2, 2020. We included a total of 82 trials randomizing 40,249 participants. Our study showed that no evidence-based treatment for COVID-19 currently exists. Very low certainty evidence indicated that corticosteroids might reduce the risk of death, serious adverse events, and mechanical ventilation. Moderate certainty evidence showed that we could reject that remdesivir reduces the risk of death by 20%. Very low certainty evidence indicated that remdesivir might reduce the risk of serious adverse events. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236448 doi: medRxiv preprint Very low certainty evidence indicated that intraveneous immunoglobin might reduce the risk of death and serious adverse events, that tocilizumab might reduce the risk of serious adverse events and mechanical ventilation, and that bromhexidine might reduce the risk of non-serious adverse events. Moderate certainty evidence showed that we could reject that hydroxychloroquine reduces the risk of death and serious adverse events by 20%, and that we could reject that lopinavir-ritonavir reduces the risk of death, serious adverse events, and risk of mechanical ventilation by 20%. Otherwise, we could neither confirm nor reject the effects of other interventions for COVID-19. More trials with low risks of bias and random errors are urgently needed. For several interventions we found a large number of currently ongoing trials. The present review concludes that no evidence-based treatment currently exists for COVID-19. Previous studies [118] [119] [120] including our first edition of the present review [120] have concluded that both corticosteroids and remdesivir showed promising results. Since our last edition, we have included more trials, and we therefore have more information, causing this difference, but there are other reasons for these contrary conclusions. One previous systematic review published in JAMA assessed the association between corticosteroids and 28-day all-cause mortality and concluded that corticosteroids are effective for treating critically ill patients with COVID-19 in reducing all-cause mortality [118] . This review assessed the certainty of evidence for all-cause mortality to be moderate, while we assessed the certainty of evidence to be very low. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020. 11.22.20236448 doi: medRxiv preprint Our present results showed a discrepancy between the random-effects meta-analysis result and the fixed-effect meta-analysis result (due to heterogeneity) of corticosteroids versus control interventions when assessing all-cause mortality, i.e., the fixed-effect meta-analysis indicated a more beneficial effect of corticosteroids. Due to the discrepancy between the random-effects and the fixed-effect model we believe that these results should be interpreted with great caution considering the uncertainty of the evidence. Furthermore, the meta-analytic effect estimate was 0.89 which may be considered relatively small. The U.S. Food and Drug Administration (FDA) recently approved remdesivir for use in adult and pediatric patients 12 years of age and older for the treatment of COVID-19 requiring hospitalization [121] . Based on the current evidence, we conclude that remdesivir is not effective in reducing allcause mortality, neither for patients not requiring oxygen nor for patients requiring oxygen or respiratory support at baseline. There was a discrepancy between the random-effects and the fixedeffect meta-analysis (due to heterogeneity) of remdesivir versus control on serious adverse events, i.e., the fixed-effect meta-analysis indicated a more beneficial effect of remdesivir. Due to the discrepancy between the random-effects and the fixed-effect model we believe that these results should be interpreted with great caution considering the uncertainty of the evidence. On all other outcomes when assessing the effects of remdesivir, we conclude that more information is needed to confirm or reject the effects of remdesivir. Hence, the clinical effects of remdesivir are unclear based on current evidence. Our results are similar to the results of a preprint of an international collaborative meta-analysis of randomized clinical trials assessing mortality outcomes with hydroxychloroquine and chloroquine for participants with COVID-19 [122] . This review included some unpublished data [122] . We have . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236448 doi: medRxiv preprint contacted the trialists of the trials that provided unpublished data for this review, but we have not received any data yet. Nevertheless, our conclusions that hydroxychloroquine does not reduce mortality in COVID-19 patients are the same [122] . Although we could exclude an intervention effect at 20% or above for most of our interventions with our trial sequential analyses, we did not assess smaller and still worthwhile intervention effects. If patients and investigators feel that such smaller intervention effects are worth pursuing, then we recommend the conduct of trials with much larger sample sizes than the ones we have identified in the present systematic review. That will require more national and international collaboration [123] . Our living systematic review has a number of strengths. The predefined methodology was based on the Cochrane Handbook for Systematic Reviews of Interventions [11] , the eight-step assessment suggested by Jakobsen et al. [17] , and trial sequential analysis [22] . Hence, this review considers both risks of systematic errors and risk of random errors. Another strength is the living systematic review design, which allows us to continuously surveil and update the evidence-base of existing interventions for treatment of COVID-19 resulting in a decreased timespan from publication of our results to optimization of clinical practice. This is particularly important in this international healthcare crisis, where a large number of new randomized clinical trials are continuously registered and published. Our living systematic review also has limitations. First, the primary limitation is the paucity of trials currently available, and the results from most current meta-analyses are of low or very low certainty. This must be considered when interpreting our meta-analysis results. Second, the trials . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236448 doi: medRxiv preprint that we included were all at risks of systematic errors so our results presumably overestimate the beneficial effects and underestimate the harmful effects of the included interventions [124] [125] [126] [127] [128] [129] [130] [131] . Third, it was not relevant to perform individual patient data meta-analyses, network-meta-analysis, or several of the planned subgroup analyses due to lack of relevant data. We contacted all trial authors requesting individual patient data, but until now we only received five datasets [38,69,79,80,107]. We did not perform network meta-analysis because the ranking of the interventions is not unclear, i.e., no evidence-based intervention currently exits for COVID-19. Fourth, we included 'time to clinical improvement' as an outcome post hoc. We did not initially plan to assess 'time to clinical improvement' [8] because this outcome is poorly defined and if outcome assessors are not adequately blinded, assessments of 'improvement' may be biased. Furthermore, time to clinical improvement is not one of the most patient-important outcomes. As an example, most patients would rather survive without complications than recover a few days sooner. Fifth, the included trials assessed the outcomes at different time points, which might contribute to increased heterogeneity. Sixth, some data are included from preprints, and these might be subject to change following peer-review. Therefore, some results, bias risk assessments, and GRADE summaries might change in later editions of this living systematic review following inclusion of the published peer-reviewed manuscripts. We have identified two important reviews that are comparable to our present project [119, 132] . The first is a network meta-analysis published in BMJ [119] . However, this review only includes drug treatments for COVID-19, does not include individual patient data meta-analyses, and does not use trial sequential analysis or similar methods to handle problems with multiplicity (repeating updating of meta-analysis, multiple comparisons due to inclusion of multiple interventions, assessing multiple outcomes). . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236448 doi: medRxiv preprint The second project is a living mapping of ongoing randomized clinical trials with network metaanalysis on all interventions for COVID-19 [132] . The authors are producing and disseminating preliminary results through an open platform [132] . This review includes both prevention and treatment and does not use trial sequential analysis or similar methods to handle problems with multiplicity (repeating updating of meta-analysis, multiple comparisons due to inclusion of multiple interventions, assessing multiple outcomes) [8] . No evidence-based treatment for COVID-19 currently exists. Very low certainty evidence indicates that corticosteroids might reduce the risk of death, serious adverse events, and mechanical ventilation; that remdesivir might reduce the risk of serious adverse events; that intraveneous immunoglobin might reduce the risk of death and serious adverse events; that tocilizumab might reduce the risk of serious adverse events and mechanical ventilation, and that bromhexidine might reduce the risk of non-serious adverse events. More trials with low risks of bias and random errors are urgently needed. This review will continuously inform best practice in treatment and clinical research of COVID-19. We erroneously reported the adjusted TSA alpha as 2% in our published protocol [8] . This has now been corrected to 3.3% according to two primary outcomes [17] . Further, we included 'time to clinical improvement' as an outcome post hoc. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236448 doi: medRxiv preprint Acknowledgements Not applicable . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236448 doi: medRxiv preprint systematic reviews and meta-analyses: the PRISMA statement. PLOS Med, 2009, 6(7), DOI: https://doi.org/10.1371/journal.pmed.1000097 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236448 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2020. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2020. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2020. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2020. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2020. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2020. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236448 doi: medRxiv preprint S14 CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236448 doi: medRxiv preprint S34 CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236448 doi: medRxiv preprint S53 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236448 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236448 doi: medRxiv preprint Clinical characteristics of coronavirus disease 2019 in China Novel Coronavirus (2019-nCOV) A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19 Clinical features of patients infected with 2019 novel coronavirus in Wuhan A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster COVID-19 associated with acute respiratory distress syndrome Covid-19 -navigating the uncharted Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration Cochrane Handbook for Systematic Reviews of Interventions version 6 A real-time dashboard of clinical trials for COVID-19 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Guideline: Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice (ICH-GCP) Evidence at a glance: error matrix approach for overviewing available evidence Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial Efficacy and safety of interferon beta-1a in treatment of severe COVID-19: a randomized clinical trial Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial Clinical outcomes and plasma concentrations of baloxavir marboxil and favipiravir in COVID-19 patients: an exploratory randomized significantly reduces respiratory morbidity in COVID-19 pneumonia: a prospective randomized trial. medRxiv. 2020 Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: preliminary results from a multi-centre, randomized A Multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19) Antiviral activity and safety of darunavir/cobicistat for the treatment of COVID-19 Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus pneumonia: results of a randomized, open-labeled prospective study The comparison of the effectiveness of lincocin® and azitro® in the treatment of covid-19-associated pneumonia: A prospective study Pulmonary radiological change of COVID-19 patients with 99mTc-MDP treatment Pulmonary rehabilitation in post-acute period of COVID-19 infection: prospective randomized controleld trial Pharmacological inhibition of the kininkallikrein system in severe COVID-19: a proof-of-concept study A randomized, open-label, controlled clinical trial of azvudine tablets in the treatment of mild and common COVID-19, a pilot study Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia: results from a randomized controlled trial Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial saline combined with usual medical care versus usual medical care alone: a randomized, open-label Interim analysis of an openlabel randomized controlled trial evaluating nasal irrigations in non-hospitalized patients with COVID-19. Int Forum Allergy Rhinol Double-blind, randomized, placebocontrolled trial with N-acetylcysteine for treatment of severe acute respiratory syndrome caused by COVID-19 Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: a randomized clinical trial A pragmatic randomized controlled trial reports the efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label Treating COVID-19 with hospitalized patients. Open Forum Infect Dis Effect of arbidol on COVID-19: a randomized controlled trial interim WHO SOLIDARITY trial results. medRxiv. 2020 Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial Efficacy of tocilizumab in patients hospitalized with COVID-19 Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial Febuxostat therapy in outpatients with Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19 Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis Drug treatments for covid-19: living systematic review and network meta-analysis Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project) FDA) News Release, FDA approves first treatment for COVID-19 Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials Evidence-based clinical practice: Overview of threats to the validity of evidence and how to minimise them Bias in clinical intervention research Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses Assessing the quality of controlled clinical trials Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials Bias due to lack of patient blinding in clinical trials. A systematic review of trials randomizing patients to blind and nonblind sub-studies Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors The Cochrane Collaboration. Living mapping and living systematic review of Covid Fixed-effect meta-analysis of corticosteroids versus control interventions (standard care or placebo) on serious adverse events